Geneva Health Forum
7th Edition: Precision Global Health in the Digital Age
10-12 April 2018
Geneva, Switzerland
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth
ISGlobal XIV Taller sobre la enfermedad de Chagas
8 March 2018
Barcelona, Spain
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation about control programmes for congenital Chagas disease
Michel Lotrowska, Acting Regional Director, DNDi Latin America – participation in the annual meeting Chagas coalition
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial
by Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I.
The Lancet Infectious Diseases, January 2018
Le Quotidien du Médecin [16 January 2018]
“Après 40 ans sans avancée, les premiers pas d’un nouveau traitement de la maladie de Chagas chronique” – “After 40 years without advance, the first steps of a new treatment for chronic Chagas disease”
18th International Congress on Infectious Diseases
1-4 March 2018
Buenos Aires, Argentina
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on Chagas disease
Byron Arana, Head of Cutaneous Leishmaniasis, DNDi – parallel symposium on cutaneous leishmaniasis
Graciela Diap, Paediatric HIV/HCV, DNDi, and Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America – parallel symposium on hepatitis C
Chagas Symposium IC-18
14-16 February 2018
London, UK
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on the progress on diagnostics and treatments for Chagas disease
Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study
by Mazzeti AL, Diniz LDF, Gonçalves KR, Nascimento AFS, Spósito PAF, Mosqueira VCF, Machado-Coelho GLL, Ribeiro I, Bahia MT.
Biochemical Pharmacology, January 2018
Increasing access to comprehensive care for Chagas disease: Development of a patient-centered model in Colombia
by Marchiol A, Forsyth C, Bernal O, Valencia C, Cucunubá Z, Pachón E, Soto M, Batista C.
Pan American Journal of Public Health, December 2017
Antileishmanial and antitrypanosomal drug identification
by Croft SL, Chatelain E, Barrett MP.
Emerging Topics in Life Sciences, December 2017
El País [19 December, 2017]
“Ocho millones de personas olvidadas” – “Eight million people forgotten”
Phenotypic screening approaches for Chagas disease drug discovery
by Chatelain E, Ioset JR.
Expert Opinion on Drug Discovery, December 2017
Regulatory Affairs Professionals Society [8 December, 2017]
“Have PRVs incentivized new rare or neglected disease research? Experts discuss”
First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease
by Ramírez JC, Parrado R, Sulleiro E, de la Barra A, Rodríguez M, Villarroel S, Irazu L, Alonso-Vega C, Alves F, Curto MA, García L, Ortiz L, Torrico F, Gascón J, Flevaud L, Molina I, Ribeiro I, Schijman AG.
PLOS ONE, November 2017
FLAP XXIV Latin American Parasitology Congress
December 10-14, 2017
Santiago de Chile, Chile
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America presented on Chagas disease at the event.
El Tiempo [26 November, 2017]
“La silenciosa batalla contra la enfermedad de Chagas” – “The silent battle against Chagas disease”
GHIT R&D Forum
December 8, 2017
Tokyo, Japan
DNDi presented at the event on the NTD Drug Discovery Booster, Chagas disease, and mycetoma.
DNDi reçoit le Prix 2017 de l’Innovation à Genève pour récompenser son action en faveur des populations les plus négligées
A l’occasion de l’Evénement économique 2017 du 9 novembre dernier, la Chambre de commerce, d’industrie et des services de Genève (CCIG), le Département de la sécurité et de l’économie (DSE) et l’Office de Promotion des Industries et des Technologies (OPI) ont décerné le Prix 2017 de l’innovation à l’initiative Médicaments contre les Maladies Négligées (DNDi).
DNDi awarded the Innovation Prize 2017 in Geneva for working to help the most neglected
As part of the ‘Evénement économique 2017’ that took place on November 9, the Geneva Chamber of Commerce, Industry and Services (CCIG), the Department of Security and Economy (DSE) and the Office for the Promotion of Industries and Technologies (OPI) awarded the Innovation Prize 2017 to the Drugs for Neglected Diseases initiative (DNDi).